American College Of Surgeons - Inspiring Quality: Highest Standards, Better Outcomes

Lori J. Goldstein, MD

Lori J. Goldstein, MD

Representing the American Society of Clinical Oncology

Dr. Lori J. Goldstein is a professor of medical oncology at Fox Chase Cancer Center (FCCC) and a nationally recognized breast cancer clinician, researcher, and leader who is driven by her passion to improve the care of breast cancer patients. She founded the Breast Evaluation Center (BEC) at FCCC, where she leads a multidisciplinary team. At FCCC, she directs the Breast Cancer Clinical Research Program, where basic, clinical, and population researchers investigate cutting-edge breast cancer prevention, detection, and treatment approaches. She also founded the Breast Cancer Survivorship Clinic to provide patients and their families with information, resources, and support.

In her own translational research program, Dr. Goldstein investigates novel molecularly targeted therapeutics. She also helped establish the FCCC Breast Tissue Registry in 1993, which has not only led to advances in our understanding of breast cancer subtypes, but has proven to be an invaluable resource for research community. As the FCCC principal investigator for the ECOG-ACRIN, she directly contributes to the national agenda in breast cancer research, actively supports the interdisciplinary involvement of FCCC investigators in ECOG-ACRIN trials, and designs and conducts national clinical studies on interventions for early and advanced stage breast cancer. She contributes to the development of evidence-based recommendations for breast cancer care as a member of the Breast Cancer Guidelines Committee for the National Comprehensive Cancer Network. In addition, she serves as the deputy associate director of clinical research. In this capacity, she actively mentors junior faculty and helped establish a partnership between FCCC and Lincoln University to train faculty and students to conduct independent biomedical and population-based cancer research.

Dr. Goldstein continues to pursue initiatives, programs, and research addressing gaps in breast cancer care, from leading nationally recognized clinical and translational breast cancer research programs, to investigating new approaches for evaluating and treating breast cancer.